Back to top

Image: Bigstock

Top Ranked Income Stocks to Buy for May 17th

Read MoreHide Full Article

Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 17th:

Salem Media Group, Inc. (SALM - Free Report) : This multimedia company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 55.6% over the last 60 days.

This Zacks Rank #1 (Strong Buy) company has a dividend yield of 12.5%, compared with the industry average of 0%. Its five-year average dividend yield is 5%.

BHP Group (BBL - Free Report) : This natural resources acquirer and developer has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.7% over the last 60 days.

This Zacks Rank #2 (Buy) company has a dividend yield of 4.8%, compared with the industry average of 0%. Its five-year average dividend yield is 5.1%.

BHP Billiton PLC Dividend Yield (TTM)

BHP Billiton PLC Dividend Yield (TTM)

BHP Billiton PLC dividend-yield-ttm | BHP Billiton PLC Quote

Target Corporation (TGT - Free Report) : This general merchandise retailer has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 60 days.

This Zacks Rank #2 company has a dividend yield of 3.6%, compared with the industry average of 1.1%. Its five-year average dividend yield is 3.3%.

Target Corporation Dividend Yield (TTM)

Target Corporation Dividend Yield (TTM)

Target Corporation dividend-yield-ttm | Target Corporation Quote

Ethan Allen Interiors Inc. (ETH - Free Report) : This interior design company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6% over the last 60 days.

This Zacks Rank #2 company has a dividend yield of 3.4%, compared with the industry average of 0%. Its five-year average dividend yield is 2.4%.

See the full list of top ranked stocks here.

Find more top income stocks with some of our great premium screens.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>